RESUMO
Autologous fat grafting is a method that has been used for breast augmentation since last century. This case report presents a woman with non-irradiated breast requested autologous fat grafting after modified radical mastectomy for breast cancer. An external soft tissue expander was used before fat grafting. This innovative technique showed benefits for the patient, with tight skin after the operation.
Assuntos
Tecido Adiposo/transplante , Mamoplastia/métodos , Dispositivos para Expansão de Tecidos , Adulto , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/patologia , Neoplasias da Mama/cirurgia , Quimioterapia Adjuvante , Feminino , Seguimentos , Sobrevivência de Enxerto , Humanos , Imageamento por Ressonância Magnética/métodos , Mastectomia Radical Modificada/métodos , Medição de Risco , Terapia de Tecidos Moles , Expansão de Tecido/métodos , Transplante Autólogo , Resultado do TratamentoRESUMO
Exercise for cancer patients is gaining support. In the current case study, a female breast cancer patient was diagnosed with breast cancer at the age of 29 years; she underwent a left modified radical mastectomy. She developed cancer again in the opposite breast at the age of 57 years and had a right modified radical mastectomy. After the second mastectomy (the right breast), the patient received chemotherapy and radiation. Following her cancer treatments, she participated in an exercise intervention for 6 months at the University of Northern Colorado's Rocky Mountain Cancer Rehabilitation Institute. A 6-month reassessment showed that she increased her muscular strength and cardiovascular function in addition to attenuating her cancer-related fatigue and depression. It is recommended that health professionals work together to ensure that a collaborative effort is undertaken to increase functional work capacity that will significantly improve patients' quality of life.
Assuntos
Neoplasias da Mama/cirurgia , Carcinoma Ductal de Mama/cirurgia , Terapia por Exercício/métodos , Recidiva Local de Neoplasia/reabilitação , Recidiva Local de Neoplasia/cirurgia , Qualidade de Vida , Adulto , Neoplasias da Mama/patologia , Carcinoma Ductal de Mama/patologia , Feminino , Seguimentos , Humanos , Mastectomia Radical Modificada/métodos , Mastectomia Segmentar/métodos , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Período Pós-Operatório , Resultado do TratamentoRESUMO
Following modified radical mastectomy, pre- and perimenopausal (amenorrhoea for < 5 years) patients with stage II or III breast cancer received CMF (cyclophosphamide 600, methotrexate 40, 5-fluorouracil 600 mg/m2 intravenously (i.v.) every 4 weeks, 9 cycles). The effect on recurrence-free survival (RFS) and overall survival (OS) of the addition of adjuvant tamoxifen (TAM) to adjuvant chemotherapy was examined by randomisation either to no additional treatment (n = 314), or concurrently TAM 30 mg daily for 1 year (n = 320). 40% had positive, 12% negative and 48% unknown receptor status. One year after surgery 21% versus 35% (CMF + TAM versus CMF) were still menstruating (P < 0.01). With a median follow-up of 12.2 years there was no difference in RFS (10-year RFS 34% versus 35%, P = 0.81) or OS (45% versus 46%, P = 0.73). In a Cox proportional hazards model, tumour size, number of metastatic lymph nodes, frequency of metastatic nodes in relation to total number of nodes removed, degree of anaplasia, age, and menostasia within the first year after operation were significant independent prognostic factors for RFS, and the same factors except age for OS. No significant interactions with TAM were seen. Thus, in this group of pre- and perimenopausal high-risk early breast cancer patients with heterogeneous receptor status given CMF i.v., concurrent TAM for 1 year did not improve the outcome. These results do not exclude that receptor positive patients may benefit from adjuvant TAM for longer periods given sequentially to chemotherapy.